Clinical review report: Cyclosporine (VERKAZIA) (Santen Canada Inc.) indication : treatment of severe vernal keratoconjunctivitis in children from four years of age through adolescence
The objective of this CADTH Common Drug Review (CDR) report is to perform a systematic review of the beneficial and harmful effects of 0.1% cyclosporine topical ophthalmic emulsion administered as one drop four times a day for the treatment of severe vernal keratoconjunctivitis in children from four...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, January 2020
|
Edition: | Version: final (with redactions) |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this CADTH Common Drug Review (CDR) report is to perform a systematic review of the beneficial and harmful effects of 0.1% cyclosporine topical ophthalmic emulsion administered as one drop four times a day for the treatment of severe vernal keratoconjunctivitis in children from four years of age through adolescence |
---|---|
Physical Description: | 1 PDF file (68 pages) illustrations |